- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06741228
Eine doppelblinde, placebokontrollierte Phase-3-Studie (Teil A) mit einer offenen Erweiterung (Teil B) zur Bewertung von MM120 im Vergleich zu Placebo bei generalisierter Angststörung
Eine multizentrische, randomisierte, doppelblinde, placebokontrollierte, 12-wöchige Phase-3-Studie (Teil A) mit einer 40-wöchigen offenen Verlängerung (Teil B) zur Bewertung der Wirksamkeit und Sicherheit von oralem MM120 im Vergleich zu Placebo in der Studie Behandlung von Erwachsenen mit generalisierter Angststörung – Voyage
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The study will enroll up to 200 participants aged 18 to 74 years, inclusive with a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) confirmed primary diagnosis of GAD and a minimum HAM-A total score of at least 20 at Screening and Baseline without clinically relevant medical or psychiatric history.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating DT120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with DT120 based on pre-specified safety and symptom severity criteria.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
Arizona
-
Gilbert, Arizona, Vereinigte Staaten, 85234
- Lighthouse Psychiatry
-
Scottsdale, Arizona, Vereinigte Staaten, 85022
- Scottsdale Research Institute
-
-
California
-
La Jolla, California, Vereinigte Staaten, 92037
- Kadima Neuropsychiatry Institute
-
San Francisco, California, Vereinigte Staaten, 94158
- UCSF Department of Neurology
-
Santa Monica, California, Vereinigte Staaten, 90404
- Psychedelic Science Institute
-
-
Colorado
-
Denver, Colorado, Vereinigte Staaten, 80209
- Mountain View
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32256
- Clinical Neuroscience Solutions Inc.
-
Lauderhill, Florida, Vereinigte Staaten, 33319
- Segal Trials
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30331
- Atlanta Center for Medical Research
-
Decatur, Georgia, Vereinigte Staaten, 30030
- iResearch Atlanta
-
Savannah, Georgia, Vereinigte Staaten, 31405
- CenExel iResearch, LLC
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60640
- Uptown Research Institute
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02116
- Adams Clinical Boston
-
Watertown, Massachusetts, Vereinigte Staaten, 02472
- Adams Clinical Watertown
-
-
New Jersey
-
Marlton, New Jersey, Vereinigte Staaten, 08053
- Hassman Research Institute
-
-
New York
-
New York, New York, Vereinigte Staaten, 10021
- Spectrum Neuroscience and Treatment Institute
-
New York, New York, Vereinigte Staaten, 10032
- New York State Psychiatric Institute (NYSPI)
-
New York, New York, Vereinigte Staaten, 10029
- Adams Clinical Harlem
-
The Bronx, New York, Vereinigte Staaten, 10461
- Adams Clinical Bronx
-
-
Ohio
-
Cleveland, Ohio, Vereinigte Staaten, 44113
- Cleveland Clinic Lutheran Hospital
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97210
- Summit Headlands LLC
-
-
Pennsylvania
-
Moosic, Pennsylvania, Vereinigte Staaten, 18507
- Scranton Medical Institute
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Adams Clinical Philadelphia
-
-
South Carolina
-
North Charleston, South Carolina, Vereinigte Staaten, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Memphis, Tennessee, Vereinigte Staaten, 38119
- Clinical Neuroscience Solutions, Inc.
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78712
- University of Texas at Austin
-
Austin, Texas, Vereinigte Staaten, 78759
- BioBehavioral Research of Austin
-
Austin, Texas, Vereinigte Staaten, 78737
- Austin Clinical Trial Partners
-
Dallas, Texas, Vereinigte Staaten, 75231
- FutureSearch Trials of Dallas, LLC
-
DeSoto, Texas, Vereinigte Staaten, 75115
- Adams Clinical Dallas
-
-
Utah
-
Draper, Utah, Vereinigte Staaten, 84020
- Cedar Clinical Research
-
Orem, Utah, Vereinigte Staaten, 84058
- Inner Space Research
-
-
Vermont
-
Bennington, Vermont, Vereinigte Staaten, 05201
- Memory Clinic Inc.
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98104
- Seattle Neuropsychiatric Treatment Center
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Diagnosis of GAD per DSM-5
- Male or female aged 18 to 74
- HAM-A Total Score ≥20
Exclusion Criteria:
- Certain psychiatric disorders (other than generalized anxiety disorder)
- First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
- Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
- Any clinically significant unstable illness
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Arm 1 - Placebo
A substance that is designed to have no therapeutic value |
A substance that is designed to have no therapeutic value |
|
Experimental: Arm 2 - 100µg DT120
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A) |
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change from Baseline in Hamilton Anxiety Rating Scale (HAM-A) total score at Week 12
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical Global Impression - Improvement (CGI-I) Scale score at each timepoint assessed during the 12-week double-blind period
Zeitfenster: Day 2 to Week 12
|
The CGI-I scale is used to measure the clinician's assessment of how much the participant's illness has improved or worsened relative to Baseline (Visit 2). The CGI-I comprises one item with 7 possible ratings (1-7 points), where a lower score indicates improvement, and a higher score indicates worsening. |
Day 2 to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Zeitfenster: Baseline to Week 12
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Zeitfenster: Baseline to Week 12
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - EuroQol-5 Dimensions - 5 Levels (EQ-5D-5L)
Zeitfenster: Baseline to Week 12
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 12
|
|
Change from Baseline in the Changes in Sexual Functioning Questionnaire (CSFQ-14) total score at each timepoint assessed during the double-blind period
Zeitfenster: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Percent of men and women with normal and abnormal sexual functioning at each timepoint assessed during the double-blind period
Zeitfenster: Baseline to Week 12
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
Baseline to Week 12
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in MADRS total score
Zeitfenster: Baseline to Week 52
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Clinical Global Impression - Severity (CGI-S) Scale score
Zeitfenster: Baseline to Week 52
|
The CGI-S scale assesses the clinician's impression of the participant's current severity of illness relative to the clinician's experience with patients who have the same diagnosis. The CGI-S comprises one item with 7 possible ratings (1-7 points), where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in Patient Global Impression - Severity (PGI-S) Scale score
Zeitfenster: Baseline to Week 52
|
The PGI scale is the patient-reported outcome (PRO) counterpart to the CGI scale. The PGI-S comprises one participant-completed item with 5 possible ratings (1-5) where a higher score indicates more severe illness. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in WPAI-SHP
Zeitfenster: Baseline to Week 52
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 52
|
|
Change from Double-blind Baseline throughout the 40-week open-label period at each timepoint assessed in EQ-5D-5L
Zeitfenster: Baseline to Week 52
|
The EuroQol 5 Dimension 5 Level (EQ-5D-5L) is a self-reported outcome measure used to evaluate health outcomes over a wide range of health conditions and treatments. The EQ-5D consists of the EQ-5D descriptive system and the EQ visual analogue scale (VAS). |
Baseline to Week 52
|
|
Percent men and women with normal and abnormal sexual functioning at each timepoint assessed during the open-label period
Zeitfenster: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
|
Change from Baseline in HAM-A total score at Week 8, Week 4, Week 2, and Week 1
Zeitfenster: Week 8, Week 4, Week 2, and Week 1
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Week 8, Week 4, Week 2, and Week 1
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 12-week double-blind period
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 12-week double-blind treatment period
Zeitfenster: Baseline to Week 12
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in - Montgomery-Åsberg Depression Rating Scale (MADRS) total score
Zeitfenster: Baseline to Week 12
|
The MADRS is used to assess depression severity and to detect changes due to antidepressant treatment. The MADRS includes 10 clinician-completed items. Each of the 10 questions is scored with a range of 0-6 points. An item score of 0 indicates item not present or normal, while an item score of 6 indicates severe or continuous presence of the symptoms. The total possible score is 60, and higher scores represent a more severe condition. |
Baseline to Week 12
|
|
Change from Baseline throughout the 12-week double-blind period at each timepoint assessed in -Work Productivity and Activity Impairment Specific Health Problem Questionnaire (WPAI-SHP)
Zeitfenster: Baseline to Week 12
|
The WPAI-SHP is a 6-item questionnaire, with a recall period of the past 7 days. The WPAI measures impairments in both paid work and unpaid work. It measures absenteeism, presenteeism as well as impairment in unpaid activity because of the health problem under study. |
Baseline to Week 12
|
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period
Zeitfenster: Day 1 to Week 52
|
Percent of participants requiring one, two, three, four, or five doses of DT120 during the 52-week study (Part A and Part B) as assessed by participants meeting protocol-specified retreatment criteria during the 40-week open-label period |
Day 1 to Week 52
|
|
Time to first treatment or lack of efficacy in the open-label period (Part B)
Zeitfenster: Day 1 to Week 52
|
Measured as time from first dosing in the Double-blind period to participant meeting HAM-A criteria for re-dose or meeting criteria for lack of efficacy |
Day 1 to Week 52
|
|
Need for DT120 treatment as assessed by the average number of DT120 treatments during the study
Zeitfenster: Day 1 to Week 52
|
Average number of treatments assessed from first dose in the double-blind period through completion of the open label extension. |
Day 1 to Week 52
|
|
HAM-A response (reduction from Baseline score of ≥50%) at each timepoint assessed during the 40-week open-label period
Zeitfenster: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
HAM-A remission (total score ≤7) at each timepoint assessed during the 40-week open-label period
Zeitfenster: 40 week open label period
|
The HAM-A consists of the following 14 items that encompass both psychological and somatic symptoms of anxiety. Each item is scored on a scale of 0 (not present) to 4 (severe), with a total score range of 0-56, where <17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. |
40 week open label period
|
|
CSFQ-14 total score at each timepoint assessed during the open-label period
Zeitfenster: 40 week open label period
|
The CSFQ-14 is a structured self-reported questionnaire designed to measure illness- and medication-related changes in sexual functioning that consists of 14 items measuring sexual functioning as a total score (14 items). There is a male and female version of the CSFQ-14 scale and a total score of less than 47 for men and less than 41 for women indicates sexual dysfunction. Lower scores are associated with worsened sexual functioning. |
40 week open label period
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- MM120-300
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .